Literature DB >> 7050440

Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group.

.   

Abstract

The Multiple Risk Factor Intervention Trial was a randomized primary prevention trial to test the effect of a multifactor intervention program on mortality from coronary heart disease (CHD) in 12,866 high-risk men aged 35 to 57 years. Men were randomly assigned either to a special intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels, or to their usual sources of health care in the community (UC). Over an average follow-up period of seven years, risk factor levels declined in both groups, but to a greater degree for the SI men. Mortality from CHD was 17.9 deaths per 1,000 in the SI group and 19.3 per 1,000 in the UC group, a statistically nonsignificant difference of 7.1% (90% confidence interval, -15% to 25). Total mortality rates were 41.2 per 1,000 (SI) and 40.4 per 1,000 (UC). Three possible explanations for these findings are considered: (1) the overall intervention program, under these circumstances, does not affect CHD mortality; (2) the intervention used does affect CHD mortality, but the benefit was not observed in this trial of seven years' average duration, with lower-than-expected mortality and with considerable risk factor change in the UC group; and (3) measures to reduce cigarette smoking and to lower blood cholesterol levels may have reduced CHD mortality within subgroups of the SI cohort, with a possibly unfavorable response to antihypertensive drug therapy in certain but not all hypertensive subjects. This last possibility was considered most likely, needs further investigation, and lends support to some preventive measures while requiring reassessment of others.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7050440

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  250 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

2.  Research into complementary and alternative medicine: problems and potential.

Authors:  R L Nahin; S E Straus
Journal:  BMJ       Date:  2001-01-20

Review 3.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

Review 4.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 5.  [Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations].

Authors:  M Siepmann; W Kirch
Journal:  Med Klin (Munich)       Date:  1998-12-15

6.  [Lack of conviction about vaccination in certain Quebec vaccinators].

Authors:  M Dionne; N Boulianne; B Duval; F Lavoie; N Laflamme; J Carsley; L Valiquette; S Gagnon; L Rochette; G De Serres
Journal:  Can J Public Health       Date:  2001 Mar-Apr

7.  Partnerships for the design, conduct, and analysis of effectiveness, and implementation research: experiences of the prevention science and methodology group.

Authors:  C Hendricks Brown; Sheppard G Kellam; Sheila Kaupert; Bengt O Muthén; Wei Wang; Linda K Muthén; Patricia Chamberlain; Craig L PoVey; Rick Cady; Thomas W Valente; Mitsunori Ogihara; Guillermo J Prado; Hilda M Pantin; Carlos G Gallo; José Szapocznik; Sara J Czaja; John W McManus
Journal:  Adm Policy Ment Health       Date:  2012-07

8.  Stable Angina Pectoris.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

9.  Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension.

Authors:  A Lehtonen; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Management of the hypertensive patient who smokes.

Authors:  H Pardell; R Tresserras; E Saltó; P Armario; R Hernández
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.